Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Rating of “Moderate Buy” from Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has been given a consensus rating of “Moderate Buy” by the four analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $37.50.

A number of research firms have weighed in on INTS. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings cut shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th. Wall Street Zen upgraded Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th.

Intensity Therapeutics Trading Down 6.4%

NASDAQ INTS opened at $4.40 on Friday. Intensity Therapeutics has a 12 month low of $3.51 and a 12 month high of $43.50. The company has a 50-day moving average of $4.33 and a 200-day moving average of $6.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86. The company has a market cap of $11.88 million, a P/E ratio of -0.77 and a beta of 2.78.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($1.08) by $0.12. As a group, equities analysts predict that Intensity Therapeutics will post -2.7 earnings per share for the current year.

Institutional Investors Weigh In On Intensity Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in shares of Intensity Therapeutics by 77.8% in the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after purchasing an additional 201,357 shares in the last quarter. Legacy Advisors LLC acquired a new stake in Intensity Therapeutics during the 4th quarter worth approximately $63,000. State Street Corp raised its holdings in Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares during the period. Corient Private Wealth LLC purchased a new position in Intensity Therapeutics in the fourth quarter valued at approximately $41,000. Finally, Jane Street Group LLC purchased a new position in Intensity Therapeutics in the fourth quarter valued at approximately $26,000. 3.74% of the stock is currently owned by institutional investors and hedge funds.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.